<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma Interleukin-6 (IL-6) level was measured in patients with <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>), <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Increase in the plasma level of IL-6 was observed in patients with <z:chebi fb="0" ids="16039">ITP</z:chebi> and SLE </plain></SENT>
<SENT sid="2" pm="."><plain>The plasma IL-6 level decreased with progression of the treatment for <z:chebi fb="0" ids="16039">ITP</z:chebi>, and it showed weak negative correlations with the platelet count at the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:chebi fb="0" ids="16039">ITP</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The increases in the plasma IL-6 level suggest the involvement of activation of the immune system in the pathogenesis of <z:chebi fb="0" ids="16039">ITP</z:chebi> </plain></SENT>
</text></document>